The Detection Of Circulating Tumor Cells (CTC) In Patients With NSCLC Undergoing Definitive Radiotherapy Or Chemoradiotherapy

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

204 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-09-30

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

CTC levels collected pre-surgery will be correlated with pathological samples.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer

NCT02380196

Non-small Cell Lung Cancer (NSCLC)

COMPLETED

Individualized Treatment of Patients With Advanced NSCLC: Potential Application for Circulating Tumor Cells (CTC) Molecular and Phenotypical Profiling

NCT02407327

Advanced Non Small Cell Lung Cancer

COMPLETED

Clinical Significance of Circulating Tumour Cells in Resectable Lung Cancer Patients

NCT05619562

Non Small Cell Lung Cancer Circulating Tumor Cell

COMPLETED

Circulating Tumor Cells in Lung Cancer

NCT01658332

Stage IIIB Non Small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer

TERMINATED NA

The Detection of Circulating Tumor Cells (CTCs) in Patients With Lung Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment

NCT02412384

Neoplastic Cells, Circulating

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with NSCLC who undergo radiation as part of a definitive course of treatment will be enrolled. Blood collections will be obtained before, during, and after radiotherapy. We will collect demographic and treatment data and explore \& describe the pattern of CTC detection in all patients

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

Patients with early stage NSCLC undergoing stereotactic radiotherapy

Radiotherapy

Intervention Type RADIATION

Cohort 2

Patients with locally advanced NSCLC undergoing standard chemoradiotherapy

Radiotherapy

Intervention Type RADIATION

Cohort 3

Patients with stage I-III NSCLC undergoing standard, fractionated radiotherapy alone

Radiotherapy

Intervention Type RADIATION

Cohort 4

Patients with locally advanced NSCLC undergoing standard chemoradiotherapy with the novel signal transduction inhibitor, nelfianvir.

Radiotherapy

Intervention Type RADIATION

Cohort 5

Patients with resectable stage IIIa NSCLC undergoing pre-operative chemoradiotherapy

Radiotherapy

Intervention Type RADIATION

Cohort 6

Patients with suspected (no tissue diagnosis) early stage NSCLC undergoing stereotactic radiotherapy

Radiotherapy

Intervention Type RADIATION

Cohort 7

Patients with locally advanced NSCLC undergoing stereotactic radiotherapy followed by concurrent mediastinal chemoradiotherapy

Radiotherapy

Intervention Type RADIATION

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Radiotherapy

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with biopsy-proven NSCLC who are undergoing definitive radiotherapy as a part of their treatment regimen.
* Age 18 or older
* Signed informed consent
* Patients who are incapable of providing informed consent are excluded from participating in this study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No